• Consensus Rating: Buy
  • Consensus Price Target: $26.17
  • Forecasted Upside: 46.84 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$17.82
▼ -0.68 (-3.68%)

This chart shows the closing price for FNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Paragon 28 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FNA

Analyst Price Target is $26.17
▲ +46.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Paragon 28 in the last 3 months. The average price target is $26.17, with a high forecast of $30.00 and a low forecast of $23.00. The average price target represents a 46.84% upside from the last price of $17.82.

This chart shows the closing price for FNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Paragon 28.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022Canaccord Genuity GroupBoost Target$20.00 ➝ $25.00Low
8/4/2022Needham & Company LLCBoost TargetBuy$20.00 ➝ $24.00Low
6/1/2022JMP SecuritiesReiterated RatingBuy$30.00High
5/10/2022Canaccord Genuity GroupLower Target$23.00 ➝ $20.00High
3/9/2022Bank of AmericaLower TargetBuy$30.00 ➝ $25.00High
3/9/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$25.00 ➝ $23.00High
3/9/2022Canaccord Genuity GroupLower TargetBuy$25.00 ➝ $23.00High
2/9/2022Needham & Company LLCLower TargetBuy$31.00 ➝ $25.00High
1/10/2022Needham & Company LLCReiterated RatingBuy$31.00High
11/23/2021JMP SecuritiesReiterated RatingBuy$29.00High
11/9/2021Piper SandlerInitiated CoverageOverweight$30.00High
11/9/2021Needham & Company LLCInitiated CoverageBuy$31.00High
11/9/2021JMP SecuritiesInitiated CoverageOutperform$30.00High
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/3/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Paragon 28 logo
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Read More

Today's Range

Now: $17.82
Low: $17.77
High: $18.91

50 Day Range

MA: $18.36
Low: $16.05
High: $20.60

52 Week Range

Now: $17.82
Low: $12.35
High: $25.41

Volume

128,059 shs

Average Volume

275,107 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Paragon 28?

The following sell-side analysts have issued research reports on Paragon 28 in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., JMP Securities, Needham & Company LLC, and Piper Sandler.
View the latest analyst ratings for FNA.

What is the current price target for Paragon 28?

6 Wall Street analysts have set twelve-month price targets for Paragon 28 in the last year. Their average twelve-month price target is $26.17, suggesting a possible upside of 46.8%. JMP Securities has the highest price target set, predicting FNA will reach $30.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $23.00 for Paragon 28 in the next year.
View the latest price targets for FNA.

What is the current consensus analyst rating for Paragon 28?

Paragon 28 currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FNA will outperform the market and that investors should add to their positions of Paragon 28.
View the latest ratings for FNA.

What other companies compete with Paragon 28?

How do I contact Paragon 28's investor relations team?

The company's listed phone number is 730-399-3400 and its investor relations email address is [email protected]gon28.com. The official website for Paragon 28 is www.paragon28.com. Learn More about contacing Paragon 28 investor relations.